Nicole L. Yates

Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology

United States

SCHOLARLY PAPERS

3

DOWNLOADS

155

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Lower SARS-CoV-2-Specific Humoral Immunity in People Living With HIV-1 Recovered From Symptomatic Non-Hospitalized COVID-19

Number of pages: 44 Posted: 04 Jan 2022
affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - School of Medicine, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, affiliation not provided to SSRN, Duke University - Duke Human Vaccine Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Pennsylvania - Department of Medicine, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology and affiliation not provided to SSRN
Downloads 64 (704,691)

Abstract:

Loading...

HIV-1, PLWH, People Living with HIV, SARS-CoV-2, COVID-19, humoral immunity, antibody, antibody isotype, antibody subclass, ACE-2 blocking, ADCP, antibody dependent phagocytosis, Multiplex assay, Meso Scale Discovery, IgG, IgG1, IgG3, IgA, CoVPN

2.

Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition

Number of pages: 35 Posted: 18 Oct 2022
Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University, Duke University - School of Medicine, Duke University - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Independent, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington, University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington - Department of Biostatistics, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Family Health International, Via Libre CRS, University of California, Los Angeles (UCLA) - Department of Medicine, Wits Health Consortium - Perinatal HIV Research Unit (PHRU), University of Cape Town (UCT) - Department of Medicine, University of Pennsylvania, Asociacion Civil Impacta Salud y Educacion, Emory University - School of Medicine, San Miguel Clinical Research Center - Asociacion Civil Impacta Salud y Educacion, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institute for Communicable Diseases of the National Health Laboratory Service, Duke University - Duke Human Vaccine Institute, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 56 (751,045)

Abstract:

Loading...

body weight, HIV, prevention, broadly neutralizing antibodies, monoclonal antibody, pharmacokinetics

3.

Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study

Number of pages: 23 Posted: 14 Jan 2025
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Family Health International, HPTN Leadership and Operations Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center, Harvard University - Brigham and Women’s Hospital, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Kelly Government Solutions, Columbia University - Aaron Diamond AIDS Research Center, Columbia University - Irving Medical Center, Emory University - School of Medicine, University of North Carolina (UNC) at Chapel Hill, Harvard University - Beth Israel Deaconess Medical Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Emory University - Division of Infectious Diseases, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa (CAPRISA), George Washington University - School of Medicine and Health Sciences, National Institutes of Health, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institutes of Health - Vaccine Research Center and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 35 (909,275)

Abstract:

Loading...

HIV prevention, dosing strategy, exponent of body weight, two-compartment, population pharmacokinetics model, variability in exposure